Table 2.
Factors predictive of symptomatic intracranial hemorrhage and that do not exclude intravenous thrombolysis. Results from meta-analysis and large registries
| Predictor Author | Number of trials and patients | Risk of SICH OR/RR and 95% CI | Unfavourable outcome (death or dependence) |
|---|---|---|---|
| Prior statin use Meseguer 2012 | 11 studies with 6438 patients | 1.55 (1.23-1.95) | 0.99 (0.88-1.12) NS |
| Leuko-araiosis Lin, 2106 | 11 trials, 6912 patients | 1.89 (1.51-2.37) | Not given |
| Leuko-araiosis, Charidimou 2016 | 11 studies, 7194 patients | 1.55 (1.17-2.06) | 1.61 (1.44-1.79) |
| Leuko-araiosis Kongbunkiat 2017 | 15 studies, 6967 patients | 1.65 (1.26-2.16) | 1.30 (1.19-1.42) |
| Microbleed burden Tsivgoulis 2016 | 9 studies, 2479 patients | 2.36 (1.21-4.61), risk proportional to the burden | Not given |
| Microbleed burden Charidimou 2015 | 8 studies, 1704 patients | 2.87 (1.73-4.79) | Not given |
| Microbleed burden Wang S, 2017 | 11 studies, 2702 patients | 2.14 (1.34-3.42) | 1.58 (1.08-2.31) |
| Recent ischemic stroke Merkler | Several registries with 36,599 patients | 0.9 (0.6-1.4) NS | 1.5 (1.2-1.9) |
| Antiplatelet drug use Luo 2016 | 19 studies with 108,588 patients | 1.70 (1.47-1.97) | 1.46 (1.22-1.75) |
| Antiplatelet drug use Tsivgoulis | 7 trials, 4376 patients | 1.67 (0.75-3.72) NS | 1.01 (0.55-1.86) NS |
| Antiplatelet drug Capellari 2016 | 179 centers, 15,949 patients | 2.23 (1.26-3.94) | Not given |
NS=Not significant, SICH=Symptomatic intracranial hemorrhage, OR=Odds ratio, CI=Confidence interval, RR=Relative risk